250 related articles for article (PubMed ID: 25218177)
1. Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors.
Chong CR; Wirth LJ; Nishino M; Chen AB; Sholl LM; Kulke MH; McNamee CJ; Jänne PA; Johnson BE
Lung Cancer; 2014 Nov; 86(2):241-6. PubMed ID: 25218177
[TBL] [Abstract][Full Text] [Related]
2. Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report.
Forde PM; Hooker CM; Boikos SA; Petrini I; Giaccone G; Rudin CM; Yang SC; Illei PB; Hann CL; Ettinger DS; Brahmer JR; Kelly RJ
J Thorac Oncol; 2014 Mar; 9(3):414-8. PubMed ID: 24518093
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid.
Wang X; Li Y; Duan J; Chen Y; Yuan B; Qi Z; Tan H
Oncologist; 2019 Jun; 24(6):798-802. PubMed ID: 30413666
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors.
Walter T; Planchard D; Bouledrak K; Scoazec JY; Souquet PJ; Dussol AS; Guigay J; Hervieu V; Berdelou A; Ducreux M; Arpin D; Lombard-Bohas C; Baudin E
Lung Cancer; 2016 Jun; 96():68-73. PubMed ID: 27133753
[TBL] [Abstract][Full Text] [Related]
5. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy.
Wirth LJ; Carter MR; Jänne PA; Johnson BE
Lung Cancer; 2004 May; 44(2):213-20. PubMed ID: 15084386
[TBL] [Abstract][Full Text] [Related]
6. Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience.
Herde RF; Kokeny KE; Reddy CB; Akerley WL; Hu N; Boltax JP; Hitchcock YJ
Am J Clin Oncol; 2018 Jan; 41(1):24-29. PubMed ID: 26270444
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours.
Papaxoinis G; Kordatou Z; McCallum L; Nasralla M; Lamarca A; Backen A; Nonaka D; Mansoor W
Neuroendocrinology; 2020; 110(5):413-421. PubMed ID: 31437838
[TBL] [Abstract][Full Text] [Related]
8. Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs.
Lenotti E; Alberti A; Spada F; Amoroso V; Maisonneuve P; Grisanti S; Baggi A; Bianchi S; Fazio N; Berruti A
Front Endocrinol (Lausanne); 2021; 12():669484. PubMed ID: 33986731
[TBL] [Abstract][Full Text] [Related]
9. [Pulmonary carcinoid: analysis of a single institutional experience and prognostic factors].
Correia Sda S; Pinto C; Bernardo J
Acta Med Port; 2014; 27(6):749-54. PubMed ID: 25641291
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary carcinoid tumours: indolent but not benign.
De Dosso S; Bajetta E; Procopio G; Cortinovis D; Buzzoni R; Catena L; Platania M; Verzoni E
Oncology; 2007; 73(3-4):162-8. PubMed ID: 18418008
[TBL] [Abstract][Full Text] [Related]
11. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.
Dasari A; Bergsland EK; Benson AB; Cai B; Huynh L; Totev T; Shea J; Duh MS; Neary MP; Dagohoy CG; Shih BE; Maurer VE; Chan J; Kulke MH
Oncologist; 2019 Aug; 24(8):1066-1075. PubMed ID: 30610008
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.
Caplin ME; Baudin E; Ferolla P; Filosso P; Garcia-Yuste M; Lim E; Oberg K; Pelosi G; Perren A; Rossi RE; Travis WD;
Ann Oncol; 2015 Aug; 26(8):1604-20. PubMed ID: 25646366
[TBL] [Abstract][Full Text] [Related]
13. Experience in treatment of metastatic pulmonary carcinoid tumors.
Granberg D; Eriksson B; Wilander E; Grimfjärd P; Fjällskog ML; Oberg K; Skogseid B
Ann Oncol; 2001 Oct; 12(10):1383-91. PubMed ID: 11762808
[TBL] [Abstract][Full Text] [Related]
14. Typical and atypical pulmonary carcinoids : outcome in patients presenting with regional lymph node involvement.
Thomas CF; Tazelaar HD; Jett JR
Chest; 2001 Apr; 119(4):1143-50. PubMed ID: 11296182
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
Ferolla P; Brizzi MP; Meyer T; Mansoor W; Mazieres J; Do Cao C; Léna H; Berruti A; Damiano V; Buikhuisen W; Grønbæk H; Lombard-Bohas C; Grohé C; Minotti V; Tiseo M; De Castro J; Reed N; Gislimberti G; Singh N; Stankovic M; Öberg K; Baudin E
Lancet Oncol; 2017 Dec; 18(12):1652-1664. PubMed ID: 29074099
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Chemotherapy Does Not Confer Superior Survival in Patients With Atypical Carcinoid Tumors.
Anderson KL; Mulvihill MS; Speicher PJ; Yerokun BA; Gulack BC; Nussbaum DP; Harpole DH; D'Amico TA; Berry MF; Hartwig MG
Ann Thorac Surg; 2017 Oct; 104(4):1221-1230. PubMed ID: 28760471
[TBL] [Abstract][Full Text] [Related]
17. Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of
Bongiovanni A; Recine F; Riva N; Foca F; Liverani C; Mercatali L; Nicolini S; Pieri F; Amadori D; Ibrahim T
Clin Lung Cancer; 2017 Jul; 18(4):415-420. PubMed ID: 27956089
[TBL] [Abstract][Full Text] [Related]
18. Carcinoid tumors of the lung: a report of 11 cases.
Ichiki Y; Nagashima A; Yasuda M; Takenoyama M
Asian J Surg; 2013 Jul; 36(3):116-20. PubMed ID: 23810161
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of docetaxel in patients with metastatic carcinoid tumors.
Kulke MH; Kim H; Stuart K; Clark JW; Ryan DP; Vincitore M; Mayer RJ; Fuchs CS
Cancer Invest; 2004; 22(3):353-9. PubMed ID: 15493355
[TBL] [Abstract][Full Text] [Related]
20. Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors.
Walts AE; Ines D; Marchevsky AM
Mod Pathol; 2012 Sep; 25(9):1258-64. PubMed ID: 22575865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
